T
Toyohide Shinkawa
Researcher at Kyowa Hakko Kirin Co., Ltd.
Publications - 52
Citations - 5089
Toyohide Shinkawa is an academic researcher from Kyowa Hakko Kirin Co., Ltd.. The author has contributed to research in topics: Antibody & Fragment crystallizable region. The author has an hindex of 15, co-authored 52 publications receiving 4917 citations. Previous affiliations of Toyohide Shinkawa include Yamaguchi University.
Papers
More filters
Journal ArticleDOI
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.
Toyohide Shinkawa,Kazuyasu Nakamura,Naoko Yamane,Emi Shoji-Hosaka,Yutaka Kanda,Mikiko Sakurada,Kazuhisa Uchida,Hideharu Anazawa,Mitsuo Satoh,Motoo Yamasaki,Nobuo Hanai,Kenya Shitara +11 more
TL;DR: The results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
Patent
Method for controlling the activity of immunologically functional molecule
Nobuo Hanai,Kazuyasu Nakamura,Emi Shoji,Motoo Yamasaki,Kazuhisa Uchida,Toyohide Shinkawa,Susumu Imabeppu,Yutaka Kanda,Naoko Yamane,Hideharu Anazawa +9 more
TL;DR: A method for controlling the activity of an immunologically functional molecule such as an antibody, a protein or a peptide is described in this paper, where a promoter of the activity is defined.
Patent
Antibody composition which specifically binds to cd20
TL;DR: In this paper, the authors presented an antibody composition which specifically binds to CD20 and comprises an antibody molecule which has complex N-glycoside-linked sugar chains bound to the Fc region.
Patent
Process for purifying antibody
TL;DR: In this article, a process for purifying an antibody having a desired property, which comprises using a substance having an affinity to a carbohydrate binding to the antibody, and a medicament comprising, as an active ingredient, the antibody purified by the process; and a method for diagnosing or preventing various diseases.
Journal ArticleDOI
Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma
Rinpei Niwa,Emi Shoji-Hosaka,Mikiko Sakurada,Toyohide Shinkawa,Kazuhisa Uchida,Kazuyasu Nakamura,Kouji Matsushima,Ryuzo Ueda,Nobuo Hanai,Kenya Shitara +9 more
TL;DR: The results indicate that defucosylated antibodies with enhanced ADCC as well as potent antitumor activity in vivo are promising candidates for the novel antibody-based therapy.